ZURA Stock Analysis: Buy, Sell, or Hold?
ZURA - Zura Bio Limited Class A Ordinary Shares
$4.83
0.03 (0.63%)
▲
5d:
+6.39%
30d:
-15.11%
90d:
-22.22%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Accumulation
ZURA is down 10.7% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 31 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When ZURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ZURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ZURA is currently trading at $4.83, which is considered oversold relative to its 30-day fair value range of $4.93 to $5.71.
Technical Outlook: Technically, ZURA is showing sideways momentum. Immediate support is located at $4.35, while resistance sits at $5.50.
Market Sentiment: ZURA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.67 (+224.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZURA is showing sideways momentum. Immediate support is located at $4.35, while resistance sits at $5.50.
Market Sentiment: ZURA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.67 (+224.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.93 -
$5.71
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 224.4% below Wall St target ($15.67)
Trading Range Analysis
30-Day Trading Range
$4.93 -
$5.71
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.73
(15.2%)
Support & Resistance Levels
Support Level
$4.35
Resistance Level
$5.50
Current Trend
Sideways
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-48.30
Wall Street Target
$15.67
(+224.4%)
Share & Embed Analysis
Last updated: May 14, 2026 11:32 PM ET
Data refreshes hourly during market hours. Next update: 12:32 AM
Data refreshes hourly during market hours. Next update: 12:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZURA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ai Biotechnology Llc
BUY
2000000 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$23 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 59 HOLD |
